



(11) **EP 2 295 568 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A2)
Corrections, see
Bibliography INID code(s) 71

(51) Int Cl.:
C12N 15/10 ^(2006.01) **C12N 5/10** ^(2006.01)
A61K 38/10 ^(2006.01) **C07K 7/06** ^(2006.01)

(48) Corrigendum issued on:
26.10.2011 Bulletin 2011/43

(43) Date of publication:
16.03.2011 Bulletin 2011/11

(21) Application number: **10011987.4**

(22) Date of filing: **16.10.2003**

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
AL LT LV MK

(30) Priority: **16.10.2002 EP 02292548**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
03769800.8 / 1 551 867

(27) Previously filed application:
16.10.2003 PCT/IB03/05108

(71) Applicants:
• **Centre National de la Recherche Scientifique**
75016 Paris (FR)
• **Université de la Méditerranée**
13007 Marseille (FR)
• **Schafer-N**
2100 Copenhagen (DK)

• **Universitätsklinikum Hamburg-Eppendorf**
20246 Hamburg (DE)

(72) Inventors:
• **Rougon, Geneviève**
13009 Marseille (FR)
• **Torregrossa, Pascal**
1822 Chernex (CH)
• **Schachner, Melitta**
20251 Hamburg (DE)
• **Schafer, Nielsen, Claus**
3050 Humlebaek (DK)

(74) Representative: **Leblois-Préhaud, Hélène Marthe**
Georgette et al
Cabinet Orès
36, rue de St Petersburg
F-75008 Paris (FR)

Remarks:
This application was filed on 30-09-2010 as a
divisional application to the application mentioned
under INID code 62.

(54) **Use of poly-alpha2,8-sialic acid mimetic peptides to modulate NCAM functions**

(57) The invention relates to the use of a peptide consisting of 5 to 30 amino acid residues, preferably 9 to 15, most preferably about 12 amino acid residues, said peptide comprising a B epitope of a poly- α 2,8 sialic acid attached to NCAM, which is recognized by an anti-poly- α 2,8 sialic acid (PSA) antibody, for the preparation of a

medicament for modulating NCAM functions, to be administered for the prevention and/or the treatment of neurodegenerative diseases, brain and spine lesions, age-related learning and memory problems, and cancer.

EP 2 295 568 A8